Dongcheng pharmaceutical's key product, natrium traxaparin calcium, has been approved and delayed in preparation for on-site inspection

Naltrexaparin calcium, also known as low molecular weight heparin calcium, was declared by Dongcheng pharmaceutical in May 2007 According to the company, the product is a key product developed by the company according to EU standards The workshop has passed GMP certification Once the production approval is obtained, it will be listed and promoted The competition of low molecular weight heparin calcium preparation is fierce in China, and now there are 5 enterprises producing it Among them, the low molecular weight heparin calcium for injection of freeze-dried powder injection type is only produced by Hefei Zhaoke Pharmaceutical Co., Ltd., and the low molecular weight heparin calcium injection of water injection type is involved by four enterprises, namely Changshan Pharmaceutical Co., Ltd., HongRi Pharmaceutical Co., Ltd., Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd and Hainan General Alliance Pharmaceutical Co., Ltd Among them, Changshan pharmaceutical's main product, low molecular weight heparin calcium injection, enjoys the advantage of independent pricing because its technical standard is significantly higher than the national standard, and jointly monopolizes the domestic market with GSK, the original research pharmaceutical enterprise Although the dosage forms of the products are different, but the indications are highly overlapped, the competition between Dongcheng pharmaceutical and Changshan pharmaceutical is inevitable The data shows that Changshan pharmaceutical's low molecular weight heparin calcium injection has been used as the base drug and has entered the base drug market in many provinces and cities Dongcheng pharmaceutical is mainly engaged in heparin and chondroitin sulfate In the third quarter report of 2014, the company estimated that the net profit attributable to shareholders of Listed Companies in 2014 was 90.7645 million yuan to 121.0194 million yuan, an increase of - 10% to 20% year on year.